Brain tumours are one of the most aggressive and deadly forms of cancer. They can be difficult to treat due to their location and the complexity of the brain. However, a new gel with dual benefits has been developed that effectively controls aggressive brain tumours.
The gel, called Gliadel, is a biodegradable polymer that is implanted directly into the brain during surgery. It slowly releases a chemotherapy drug called carmustine, which is known to be effective against brain tumours. The drug is released over a period of several weeks, providing a sustained dose that can kill cancer cells and prevent them from spreading.
In addition to its chemotherapy properties, Gliadel also has a physical benefit. The gel forms a barrier around the tumour, preventing it from spreading to other parts of the brain. This is particularly important for aggressive brain tumours, which can quickly spread and become difficult to treat.
Clinical trials have shown that Gliadel is effective in treating glioblastoma, one of the most aggressive forms of brain cancer. In one study, patients who received Gliadel during surgery had a median survival rate of 13.9 months, compared to 11.6 months for those who did not receive the treatment.
Gliadel is not without its side effects, however. The chemotherapy drug can cause nausea, vomiting, and other side effects commonly associated with chemotherapy. Additionally, the gel can cause swelling in the brain, which can lead to seizures and other complications.
Despite these side effects, Gliadel represents a significant advance in the treatment of aggressive brain tumours. It provides both chemotherapy and physical benefits, making it a powerful tool in the fight against cancer. As research continues, it is likely that new treatments will be developed that build on the success of Gliadel and other innovative therapies.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- Minting the Future w Adryenn Ashley. Access Here.
- Source: Plato Data Intelligence: PlatoData